Dr. Müller Pharma s.r.o.

Dr. Müller Pharma s.r.o. specializes in topical and oral pharmaceutical preparations intended for external or internal use. Their portfolio includes ultrasound gels for diagnostic imaging, lice treatments like shampoos and lotions, oral and nasal sprays (including those with aloe vera or salvia extract), lubricating gels, and vaginal gels containing hyaluronic acid. These products are designed for conditions like skin irritation, throat relief, nasal congestion, lice infestations, and vaginal dryness.

Dr. Müller Pharma s.r.o. is based in the Czech Republic, which places its devices under EU regulatory oversight. Since the company’s products fall under EU medical device classifications (Class I, IIa, and IIb), they must comply with EU Medical Device Regulations (MDR) or Medical Device Directives (MDD) depending on their risk level. This means their devices are registered in the EU’s eudamed database, ensuring traceability and transparency for regulatory purposes.

Dr. Müller Pharma’s devices are listed in the eudamed database, the official EU registry for medical devices. This platform is maintained by the European Commission and is used to track manufacturers, authorized representatives, and devices under EU regulations. Listing in eudamed ensures compliance with transparency requirements for Class I, IIa, and IIb devices, allowing healthcare professionals and regulators to verify product details.

Dr. Müller Pharma’s devices are classified as Class I, Class IIa, or Class IIb under EU medical device regulations. Classification depends on factors like the device’s intended use, risk level, and interaction with the body. For example, low-risk items like nasal sprays or lubricating gels may fall under Class I, while more involved products—such as certain lice treatments or vaginal gels—could be Class IIa or IIb due to their potential impact on patient safety. The classification determines the regulatory scrutiny and documentation requirements for each product.

The classification of a medical device depends on its intended purpose, duration of use, and potential risks to patients. For instance, Class IIa or IIb devices—such as lice treatments or vaginal gels—may involve active ingredients or prolonged contact with sensitive tissues, increasing their risk profile compared to simpler products like nasal sprays or ultrasound gels. Higher classifications trigger stricter regulatory controls, including additional clinical evaluations or post-market surveillance, to ensure safety and efficacy before authorization.